All patients
adolescents (typically 12-15 years of age) adults (typically between 18 and 65yr) age >= 55 yr age >= 60 yr age >= 65 yr age >= 75 yr alpha variant (B.1.1.7, UK) any cancer autoimmune disease beta variant (B.1.351 / 501Y.V2, South Africa) children corticosteroids: no corticosteroids: yes critical disease delta variant (B.1.617.2, Indian) dialysis patients elderly (typically over 65yr) fully vaccinated gamma variant (P.1, Brazil) haematological cancers healthcare workers immunodepression invasive ventilation kidney transplant recipients no oxygen needed non invasive oxygen obese omicron variant BA.1 (B.1.1.529) omicron variant BA.2 VOC original (Wuhan) strain positive for SARS-Cov-2 at baseline severe disease solid cancer solid organ transplant recipients subjects at risk
potential COVID-19 treatments in COVID-19 mild to moderate - Summary of results Outcome TE 95% CI n k I2 ROB Pub. bias 14-days deathsdetailed results VERU-111, 2022 0.30 [0.14; 0.64]
0.30 [0.14 ; 0.64 ] VERU-111, 2022 1 0% 150 NA not evaluable death D28detailed results CAN-COVID, 2020 0.67 [0.30; 1.50]
Somersan-Karakaya (Cohort 1, Cohort 1A; Combined doses), 2021 0.61 [0.41; 0.92]
0.62 [0.43 ; 0.90 ] CAN-COVID, 2020, Somersan-Karakaya (Cohort 1, Cohort 1A; Combined doses), 2021 2 0% 1,642 moderate not evaluable deathsdetailed results CAN-COVID, 2020 0.67 [0.30; 1.50]
Kirti, 2021 0.12 [0.01; 2.36]
Libster, 2020 0.50 [0.09; 2.71]
LIVE-AIR (Temesgen), 2021 0.70 [0.40; 1.21]
SAVE-MORE, 2021 0.45 [0.20; 0.99]
Somersan-Karakaya (Cohort 1, Cohort 1A; Combined doses), 2021 0.61 [0.41; 0.92]
0.60 [0.46 ; 0.80 ] CAN-COVID, 2020, Kirti, 2021, Libster, 2020, LIVE-AIR (Temesgen), 2021, SAVE-MORE, 2021, Somersan-Karakaya (Cohort 1, Cohort 1A; Combined doses), 2021 6 0% 2,987 moderate not evaluable deaths (time to event analysis only)detailed results LIVE-AIR (Temesgen), 2021 0.70 [0.40; 1.21]
0.70 [0.40 ; 1.21 ] LIVE-AIR (Temesgen), 2021 1 0% 479 NA not evaluable clinical deteriorationdetailed results Libster, 2020 0.52 [0.29; 0.94]
SAVE-MORE, 2021 0.36 [0.26; 0.50]
0.40 [0.29 ; 0.55 ] Libster, 2020, SAVE-MORE, 2021 2 13% 160 low not evaluable clinical improvementdetailed results CAN-COVID, 2020 1.39 [0.76; 2.54]
1.39 [0.76 ; 2.54 ] CAN-COVID, 2020 1 0% 446 NA not evaluable clinical improvement (7-day)detailed results Kirti, 2021 0.90 [0.77; 1.06]
0.90 [0.77 ; 1.06 ] Kirti, 2021 1 0% 112 NA not evaluable clinical improvement (time to event analysis only)detailed results Shinkai, 2021 1.40 [0.91; 2.15]
1.40 [0.91 ; 2.15 ] Shinkai, 2021 1 0% 156 NA not evaluable death or ventilationdetailed results LIVE-AIR (Temesgen), 2021 0.65 [0.43; 0.98]
Somersan-Karakaya (Cohort 1, Cohort 1A; Combined doses), 2021 0.66 [0.46; 0.94]
0.65 [0.50 ; 0.86 ] LIVE-AIR (Temesgen), 2021, Somersan-Karakaya (Cohort 1, Cohort 1A; Combined doses), 2021 2 0% 1,197 moderate not evaluable hospital dischargedetailed results Kirti, 2021 1.20 [0.73; 1.98]
Somersan-Karakaya (Cohort 1, Cohort 1A; Combined doses), 2021 1.48 [1.05; 2.09]
1.38 [1.04 ; 1.84 ] Kirti, 2021, Somersan-Karakaya (Cohort 1, Cohort 1A; Combined doses), 2021 2 0% 1,309 moderate not evaluable hospitalizationdetailed results Jagannathan, 2020 1.00 [0.14; 7.34]
1.00 [0.14 ; 7.34 ] Jagannathan, 2020 1 0% 120 NA not evaluable mechanical ventilationdetailed results Kirti, 2021 0.20 [0.00; 8.69]
SAVE-MORE, 2021 0.47 [0.03; 7.48]
0.35 [0.04 ; 3.24 ] Kirti, 2021, SAVE-MORE, 2021 2 0% 706 low not evaluable viral clearance detailed results Chaccour, 2020 0.92 [0.77; 1.09]
Jagannathan, 2020 0.81 [0.56; 1.18]
0.90 [0.77 ; 1.05 ] Chaccour, 2020, Jagannathan, 2020 2 0% 144 low not evaluable viral clearance (time to event analysis only)detailed results Jagannathan, 2020 0.81 [0.56; 1.18]
0.81 [0.56 ; 1.18 ] Jagannathan, 2020 1 0% 120 NA not evaluable viral clearance by day 7detailed results Chaccour, 2020 0.92 [0.77; 1.09]
Kirti, 2021 0.80 [0.43; 1.50]
0.91 [0.77 ; 1.08 ] Chaccour, 2020, Kirti, 2021 2 0% 136 low not evaluable ICU admissiondetailed results Kirti, 2021 0.90 [0.30; 2.70]
Libster, 2020 0.33 [0.07; 1.58]
0.64 [0.25 ; 1.62 ] Kirti, 2021, Libster, 2020 2 5% 272 moderate not evaluable recoverydetailed results Crippa (CANDIDATE), 2021 0.54 [0.15; 1.94]
0.54 [0.15 ; 1.94 ] Crippa (CANDIDATE), 2021 1 0% 91 NA not evaluable serious adverse eventsdetailed results CAN-COVID, 2020 0.73 [0.45; 1.19]
Jagannathan, 2020 1.00 [0.14; 7.34]
Shinkai, 2021 2.80 [0.14; 56.95]
0.77 [0.48 ; 1.22 ] CAN-COVID, 2020, Jagannathan, 2020, Shinkai, 2021 3 0% 724 moderate not evaluable adverse eventsdetailed results Chaccour, 2020 1.00 [0.20; 5.07]
Jagannathan, 2020 1.33 [0.63; 2.78]
Shinkai, 2021 19.54 [7.77; 49.11]
3.09 [0.43 ; 22.21 ] Chaccour, 2020, Jagannathan, 2020, Shinkai, 2021 3 91% 300 moderate not evaluable 0.2 5.0 1.0 relative treatment effect www.metaEvidence.org 2024-05-07 20:14 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
pathologies: 90
- treatments: 290,547,608,830,831,829,901,680,595,828,681,1209,833,629,689,543,617,625,859,511,960,546,564,944,682,1266,943,894,560,1102,598,563,668,753,752,836,639,541,534,581,615,679,522,582,666,1149,1150,737,544,733,597,524,611,538,957,958,521,566,517,881,904,882,897,896,899,1235,898,687,740,883,947,536,591,729,887,742,878,975,570,771,888,1141,690,880,1255,567,596,1437,600,652,557,635,1236,553,628,646,645,607,395,920,1438,927,932,931,1263,599,614,942,1436,928,923,535,1046,727,818,606,954,964,962,963,1045,638,677,627,533,526,616,926,1246,726,580,568,527,588,539,585,691,1210,525,843,827,1047,1048,819,545,1253,519,619,537,514,688,529,508,656,657,832,530,512,515,754,1142,1419,513,884,632,559,889,956,684,886,631,574,509,542,1145,555,554,941,961,1250,633,676,518,532,510,528,520,955,815,893,623,622,630,593,569,516,814,649,650,589,651,968,1245,610,751,747,695,548,970,594,565,879,1257,571,626,697,572,1234,586,573,540,592,930,949,838,698,934,735,929,948,946,945,587,655,1146,531,933,613,919,725,678,921,621,959,748,1348,1256,924,1243,925,658,699,612,552,590,891,605,892,722,618,609,551,834,763,922,935,620,1317,1265,824,766,857,1291,1088,1331,1330,1329,1344,1328,1327,979,822,762,805,950,757,761,806,758,826,755,821,1288,1287,1286,760,1284,802,765,1285,759,823,804,1264,764,858,835,1262,1290,1316,1341,1342,1343,825,803,1244,523,885,734,1439
- roots T: 290
